Nova Mentis Life Science Corp logo

Nova Mentis Life Science Corp

0
OTCPK:NMLSF (Canada)  
$ 0.01 0 (0%) 02:41 PM EST
At Loss
Market Cap:
$ 533.00K
Enterprise V:
$ 567.00K
Volume:
3.00K
Avg Vol (2M):
48.00K
Trade In:
Volume:
3.00K
At Loss
Avg Vol (2M):
48.00K

Business Description

Description
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.2
Equity-to-Asset -40.23
Debt-to-Equity -0.06
Debt-to-EBITDA -0.14
Interest Coverage No Debt
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3344.02
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 28.3
3-Year EPS without NRI Growth Rate 27.7
3-Year FCF Growth Rate 25.9

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 54.07
9-Day RSI 50.56
14-Day RSI 49.18
6-1 Month Momentum % -56.52
12-1 Month Momentum % -75.43

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.01
Quick Ratio 0.01
Cash Ratio 0.01
Days Sales Outstanding 78.21

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -65.3

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -1528.57
Net Margin % -1496.43
FCF Margin % -171.43
ROA % -1047.5
ROIC % -839.22
3-Year ROIIC % 12.57
ROC (Joel Greenblatt) % -3890.91

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -1.8
EV-to-EBITDA -1.81
EV-to-Revenue 27
EV-to-FCF -16.12
Earnings Yield (Greenblatt) % -55.56
FCF Yield % -6.75